Jefferies:中國ADR退市風險可能到明年1月就會消除
Jefferies援引行業檢查的消息稱,美國審計人員在香港對中國公司的現場審計似乎“進展順利,沒有大問題,應該會在未來一兩週內完成”。
Edison Lee等分析師在報告中寫道,美國公衆公司會計監督委員會(PCAOB)團隊“將返回美國,向美國證券交易委員會(SEC)作正面報告,SEC然後可能作出正式決定,宣佈所有或大多數設在中國的審計公司符合PCAOB規定”,該券商預計ADR退市風險到12月或明年1月就會消除。
有知情人士稱,美國監管機構提前完成中資公司首輪現場審計。
中概股已經連漲3日,受到審計合作進展消息的提振,週五(4日)盤前繼續飆升,小鵬汽車漲19%,嗶哩嗶哩漲14%,阿裏巴巴漲超9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.